Related Experiment Video
Updated: May 8, 2025
13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
7.8K
DNAJ-PKAc fusion heightens PLK1 inhibitor sensitivity in fibrolamellar carcinoma
Marina Chan1, Songli Zhu1, Manabu Nukaya2
1Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Gut
|April 24, 2025
Summary
Researchers identified Polo-like kinase 1 (PLK1) as a key driver of fibrolamellar carcinoma (FLC) growth. Inhibiting PLK1 effectively suppressed FLC tumors, offering a promising new therapeutic strategy for this rare liver cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling
Background:
- Fibrolamellar carcinoma (FLC) is a rare, fatal liver cancer with no effective treatments.
- The DNAJ-PKAc fusion oncoprotein drives FLC, but its precise role in tumor growth is unclear.
Purpose of the Study:
- To identify protein kinase-mediated signaling networks driving FLC growth and proliferation.
- To elucidate the mechanism by which DNAJ-PKAc promotes FLC tumorigenesis.
Main Methods:
- Utilized preclinical FLC models and a polypharmacology approach to identify downstream kinases.
- Integrated functional screening and computational analysis.
- Validated findings in patient-derived mouse models and human tumors.
Main Results:
- Polo-like kinase 1 (PLK1) was identified as essential for FLC cell viability.
- PLK1 inhibition (genetic and pharmacologic) reduced FLC cell growth and induced apoptosis.
- DNAJ-PKAc directly interacts with PLK1, promoting its activation and mitotic progression; PLK1 inhibitors suppressed FLC tumor growth in preclinical models.
Conclusions:
- DNAJ-PKAc rewires signaling networks crucial for FLC progression.
- PLK1 is a viable therapeutic target for fibrolamellar carcinoma.
- Targeting PLK1 offers a promising clinical strategy for FLC treatment.
More Related Videos
13:38Monitoring Kinase and Phosphatase Activities Through the Cell Cycle by Ratiometric FRET
Published on: January 27, 2012
14.2K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.2K
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:09Cytoskeletal Linker Proteins - Plakins
2.2K
Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
2.2K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:34Inhibition of Cdk Activity
4.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K
01:22PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
01:19Interactions Between Signaling Pathways
6.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.1K